437 related articles for article (PubMed ID: 28991932)
81. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
82. In brief: GI effects of GLP-1 receptor agonists.
Med Lett Drugs Ther; 2023 Nov; 65(1690):191-192. PubMed ID: 37983121
[No Abstract] [Full Text] [Related]
83. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Mansur RB; Rosenblat JD; Kwan ATH
Expert Opin Drug Saf; 2024 Jan; 23(1):47-55. PubMed ID: 38087976
[TBL] [Abstract][Full Text] [Related]
84. Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
Kan M; Fu H; Xu Y; Yue Z; Du B; Chen Q; Wang X; Yu S; Zhang Z
Diabetes Obes Metab; 2023 Nov; 25(11):3223-3234. PubMed ID: 37529870
[TBL] [Abstract][Full Text] [Related]
85. GLP-1 receptor agonists: A review of glycemic benefits and beyond.
Clark L
JAAPA; 2024 Apr; 37(4):1-4. PubMed ID: 38531038
[TBL] [Abstract][Full Text] [Related]
86. Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.
Hachuła M; Kosowski M; Basiak M; Okopień B
Medicina (Kaunas); 2024 May; 60(6):. PubMed ID: 38929525
[No Abstract] [Full Text] [Related]
87. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
Zhang Z; Zhang Q; Tan Y; Chen Y; Zhou X; Liu S; Yu J
Front Endocrinol (Lausanne); 2023; 14():1149328. PubMed ID: 37484944
[TBL] [Abstract][Full Text] [Related]
88. [Not Available].
Salvador J; Gaztambide S
Med Clin (Barc); 2014; 143 Suppl 2():1. PubMed ID: 25326835
[No Abstract] [Full Text] [Related]
89. GLP-1: target for a new class of antidiabetic agents?
Edwards CM
J R Soc Med; 2004 Jun; 97(6):270-4. PubMed ID: 15173327
[No Abstract] [Full Text] [Related]
90. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
Athyros VG; Katsiki N; Tentolouris N
Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
[No Abstract] [Full Text] [Related]
91. Which incretin-based therapy for type 2 diabetes?
Scheen AJ
Lancet; 2014 Oct; 384(9951):1325-7. PubMed ID: 25018117
[No Abstract] [Full Text] [Related]
92. Albiglutide: a unique GLP-1 receptor agonist.
Rendell MS
Expert Opin Biol Ther; 2016 Dec; 16(12):1557-1569. PubMed ID: 27677385
[TBL] [Abstract][Full Text] [Related]
93. Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats.
Evans B; Stoltzfus B; Acharya N; Nyland JE; Arnold AC; Freet CS; Bunce SC; Grigson PS
Brain Res Bull; 2022 Oct; 189():163-173. PubMed ID: 36038016
[TBL] [Abstract][Full Text] [Related]
94. Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.
Maselli DB; Lee D; Bi D; Jirapinyo P; Thompson CC; Donnangelo LL; McGowan CE
Obes Surg; 2024 Jul; 34(7):2369-2374. PubMed ID: 38753265
[TBL] [Abstract][Full Text] [Related]
95. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
[TBL] [Abstract][Full Text] [Related]
96. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
Jensterle M; Janež A
Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347
[TBL] [Abstract][Full Text] [Related]
97. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ; Bodicoat DH
PLoS One; 2015; 10(6):e0126769. PubMed ID: 26121478
[TBL] [Abstract][Full Text] [Related]
98. Treatment Outcomes and Tolerability Following Initiation of GLP-1 Receptor Agonists Among Type 2 Diabetes Patients in Primary Care Practices in Germany.
Qiao Q; Johnsson K; Grandy S; Kostev K
J Diabetes Sci Technol; 2017 Mar; 11(2):272-277. PubMed ID: 27470665
[TBL] [Abstract][Full Text] [Related]
99. Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.
Rachman J
Diabet Med; 2004 Jan; 21 Suppl 1():18-20. PubMed ID: 15088933
[No Abstract] [Full Text] [Related]
100. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
Monami M; Dicembrini I; Marchionni N; Rotella CM; Mannucci E
Exp Diabetes Res; 2012; 2012():672658. PubMed ID: 22675341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
